Drug Policy Watch · State Brief 2026

Nevada

Snapshot (structured)

Adult-use cannabis: Legal since 2016 (Question 2), retail sales since July 1, 2017; possession up to 2.5 oz flower / 0.25 oz concentrate as of Jan 1, 2024.
Medical cannabis: Legal since 2000; medical and adult-use retail now merged under a single dual license.
Home grow: Allowed but restricted; up to 6 plants per person / 12 per household only if you live 25+ miles from a licensed dispensary.
Intoxicating hemp / hemp THC: Restricted as of 2025; intoxicating hemp products (delta-8, delta-10, THC-O, HHC, high-THC, etc.) channeled to licensed dispensaries only under SB 356 (2025).
Psychedelics: Not decriminalized; no therapeutic-access program yet. A state psychedelic pilot bill (AB 378, 2025) died; a working group has recommended a regulated-access framework.
Broad decriminalization: No broad drug decriminalization; standard controlled-substances penalty structure remains.
Harm reduction: Active state programs distribute naloxone and test strips; note fentanyl-test-strip paraphernalia exemption reportedly lapsed Jan 1, 2024 (see Harm reduction section).
Governor (party): Joe Lombardo (Republican).
Legislature control: Democratic majorities in both the Assembly and the Senate (control confirmed for the 2025 session; see Political landscape).
Citizen ballot initiatives allowed: Yes; Nevada permits citizen-initiated statutes and constitutional amendments.
Enclosure pressure score: 4/5

Cannabis

Nevada voters legalized adult-use cannabis through Question 2 in November 2016, with licensed retail sales beginning July 1, 2017. Medical cannabis has been legal since a 2000 constitutional amendment. The independent Cannabis Compliance Board (CCB), created in 2019 under AB 533 and modeled on the state's gaming regulator, licenses and enforces the entire cannabis program, having taken over from the Department of Taxation. Source: https://ccb.nv.gov/ and https://www.mpp.org/states/nevada/

Possession limits were raised by SB 277 (2023, signed by Gov. Lombardo), effective January 1, 2024, to 2.5 ounces of flower and one-quarter ounce of concentrate. Source: https://norml.org/blog/2023/12/27/nevada-new-marijuana-possession-limits-set-to-take-effect/

Home cultivation is permitted but narrowly: a person may grow up to 6 plants (12 per household) only if they reside 25 or more miles from an operating retail dispensary, which excludes most urban residents near Las Vegas and Reno. Source: https://nevadastatecannabis.org/laws and https://www.mpp.org/states/nevada/

Market structure: Nevada uses a dual state-plus-local licensing framework; both CCB approval and local jurisdiction approval are required. Recreational retailers now automatically serve medical patients under a merged "dual license," a change made in the 2025 session. Taxes are a 10% retail excise tax on adult-use sales plus a 15% wholesale excise tax on fair market value at the cultivation-to-production/retail transfer. The market is heavily tied to Las Vegas tourism and features significant multistate operator (MSO) presence; sales have come down from 2021 peaks. Source: https://nevadastatecannabis.org/laws and https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/

Consumption lounges: Nevada authorized cannabis consumption lounges (statute enacted 2021), and the CCB has been licensing them, with the first lounges approved and additional lounges (primarily in Las Vegas) advancing. Source: https://www.marijuanamoment.net/nevada-officials-give-final-approval-to-states-first-marijuana-consumption-lounge-set-to-open-this-month/ and https://www.reviewjournal.com/news/politics-and-government/nevada/3-more-marijuana-consumption-lounges-coming-to-nevada-2892180/

Key 2025-2026 actions: The 2025 session (Nevada's legislature is biennial and meets only in odd years) passed roughly seven cannabis-related bills. SB 195 cut and capped various fees, reassessed penalties for operating violations, and created the dual retail/medical license, saving operators tens of thousands of dollars per year and expanding retail access. SB 168 revised packaging, labeling, and single-package THC limits and the definition of usable cannabis. SB 41 tied a cannabis license to obtaining a cannabis tax permit. SB 25 gave the State Fire Marshal inspection authority over production facilities. Source: https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/ and https://connorpllc.com/2025-legislative-session-relating-to-cannabis/ and https://legiscan.com/NV/bill/SB168/2025

Hemp

SB 356 (2025) is the keystone hemp update. It defines a "consumable hemp product" as a hemp commodity for human consumption with THC at or below 0.3%, and requires that any hemp-derived cannabinoid product intended to be intoxicating (delta-8, delta-10, THC-O, HHC, and other synthetic or semi-synthetic forms, as well as high-THC items) be sold exclusively through licensed cannabis dispensaries, not convenience stores, gas stations, or general retail. Reported potency caps for qualifying intoxicating hemp products are 10 mg THC per serving and 100 mg per package, matching adult-use edible rules. AB 504 (2025) added deceptive-trade-practice provisions targeting unlicensed sellers of hemp products for human consumption. Source: https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/nevada-2025-intoxicating-hemp-dispensary-only and https://burningdaily.com/blogs/learn/nevada-cannabis-hemp-laws

Exposure to federal hemp changes: In November 2025, H.R. 5371 (the Continuing Appropriations and Extensions Act of 2026) closed the federal 2018 Farm Bill "hemp loophole" via Section 781, redefining hemp around a total-THC standard (0.3% total THC including THCA and isomers) and limiting finished consumer products to roughly 0.4 mg total THC per container. These federal changes take effect November 12, 2026. Source: https://legislativeanalysis.org/wp-content/uploads/2025/12/Hemp-Loophole-Fact-Sheet.pdf and https://www.cannabisbusinesstimes.com/hemp/news/15823852/s-house-passes-2026-farm-bill-intoxicating-hemp-product-ban-remains

Because Nevada already routed intoxicating hemp into the licensed dispensary channel in 2025, the state is comparatively well positioned relative to the November 12, 2026 federal deadline; intoxicating hemp products that survive will largely already be inside the regulated cannabis system, while the federal change will further squeeze any remaining unregulated channel. The precise interaction between SB 356's dispensary-only rule and the new federal total-THC definition for non-intoxicating CBD products is not fully settled and should be treated as unconfirmed pending CCB guidance. Source: https://csgmidwest.org/2026/06/04/farm-bill-loophole-has-led-to-a-booming-industry-for-hemp-derived-products-and-a-mix-of-state-laws-a-new-federal-framework-is-coming-soon/

Psychedelics

Nevada has not decriminalized psilocybin or other psychedelics and has no operating therapeutic-access program. In 2023, SB 242 created a Psychedelic Medicines Working Group housed under the Department of Health and Human Services (a 15-member body) to study psilocybin, psilocin, 5-MeO-DMT, mescaline, and ibogaine for conditions such as PTSD, substance use disorder, and major depressive disorder. The working group issued a December report recommending a state-regulated access program for psychedelic-assisted therapy and reduced penalties. Source: https://www.dhs.nv.gov/Resources/Psychedelic_Medicines_Working_Group and https://www.marijuanamoment.net/nevada-government-task-force-calls-for-state-regulated-psychedelics-program-and-reduced-penalties/ and https://www.leg.state.nv.us/Division/Research/Documents/RTTL_2023_SB242_2024.pdf

In the 2025 session, AB 378 ("Alternative Therapy Pilot Program," BDR 40-820) would have created a medically supervised pilot allowing veterans and first responders with certain mental health conditions to access psilocybin, DMT, ibogaine, mescaline, and psilocin, overseen by the Division of Public and Behavioral Health. It cleared the Assembly Health and Human Services Committee in April 2025 but died without final passage (it was not vetoed; it failed to advance through the full legislature). Source: https://www.marijuanamoment.net/nevada-lawmakers-approve-bill-to-create-psychedelic-therapy-pilot-program/ and https://thenevadaindependent.com/article/nv-stops-short-of-decriminalizing-magic-mushrooms-some-call-transformative-for-mental-health and https://trackbill.com/bill/nevada-assembly-bill-378-creates-the-alternative-therapy-pilot-program-bdr-40-820/2688912/

2026 bills: None. Nevada's legislature is biennial and does not hold a regular session in 2026; the next chance for a psychedelics bill is the 2027 regular session. The lead sponsors associated with the 2025 effort were Sen. Rochelle Nguyen and Assemblyman Max Carter (per Las Vegas Weekly reporting); treat exact sponsorship of AB 378 as worth re-verifying against the official bill record. Source: https://lasvegasweekly.com/news/2025/feb/13/nevada-lawmakers-bills-psychedelic-therapy/

Broader drug policy

Decriminalization: Nevada has no broad drug decriminalization. Controlled-substance possession remains subject to the standard penalty structure, though prior reforms reduced some low-level penalties. Source: https://norml.org/laws/nevada-penalties-2/

Harm reduction: State programs are active. Between July 1, 2024 and June 30, 2025, Nevada distributed 56,880 two-dose naloxone units, 108,050 fentanyl test strips, and 58,400 xylazine test strips, and identified three organizations (Roseman, Vitality, Westcare) to run regional mobile harm-reduction units. Naloxone and test strips are available without prescription through local health districts such as the Southern Nevada Health District. However, reporting indicates Nevada's statutory exemption of fentanyl test strips from the drug-paraphernalia definition reverted to prior (non-exempting) language as of January 1, 2024; the current paraphernalia status of test strips should be treated as unconfirmed and worth verifying against statute. Source: https://ag.nv.gov/uploadedFiles/agnvgov/Content/About/Administration/7.9.25%20SURG%20PPT.pdf and https://www.southernnevadahealthdistrict.org/programs/substance-use-and-overdose-prevention/harm-reduction/ and https://nevadacurrent.com/briefs/health-district-reminds-public-free-fentanyl-test-strips-naloxone-are-available/

Sentencing and expungement: Nevada does not offer "expungement" but provides record sealing. AB 192 (2019, the Nevada Second Chance Act, signed by then-Gov. Sisolak, effective July 1, 2019) lets people convicted of marijuana activity that has since been decriminalized or legalized petition the court to seal those records with no filing fee; it is petition-based, not automatic. Source: https://norml.org/news/2019/06/06/nevada-governor-signs-measure-sealing-past-marijuana-convictions/ and https://ccresourcecenter.org/state-restoration-profiles/nevada-restoration-of-rights-pardon-expungement-sealing/

Overdose and treatment policy: The Attorney General's Statewide Substance Use Response Working Group (SURG) coordinates opioid-settlement-funded overdose and treatment strategy and continues to meet (e.g., a July 9, 2025 meeting). Source: https://ag.nv.gov/uploadedFiles/agnvgov/Content/About/Administration/7.9.25%20SURG%20PPT.pdf

Political landscape

Governor: Joe Lombardo (Republican), who signed the 2025 cannabis and hemp bills (including SB 277 in 2023 and the 2025 package). Source: https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/

Legislature: Democrats hold majorities in both the Assembly and the Senate; the 2025 cannabis package passed with bipartisan support in the Democrat-controlled legislature. Exact 2026 seat counts and any post-2024-cycle changes should be verified, but party control of both chambers by Democrats is well established for the 2025 session. Source: https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/ and https://thenevadaindependent.com/article/nevada-policy-tracker-a-quick-guide-to-key-issues-in-the-2025-legislative-session

Key committees: Senate Commerce and Labor (cannabis and hemp commerce bills) and Assembly Health and Human Services (psychedelics and health bills) handled the major 2025 measures. Source: https://archive.leg.state.nv.us/Session/83rd2025/Minutes/Senate/CL/Final/545.pdf and https://archive.leg.state.nv.us/Session/83rd2025/Exhibits/Assembly/HHS/AHHS573P.pdf

Reform champions: On psychedelics, Sen. Rochelle Nguyen and Assemblyman Max Carter are named in reporting as backers of psychedelic-therapy legislation. Source: https://lasvegasweekly.com/news/2025/feb/13/nevada-lawmakers-bills-psychedelic-therapy/ Named opponents and the specific legislators who blocked AB 378's final passage are unconfirmed in the sources reviewed; treat as unconfirmed.

Ballot initiatives

Nevada permits citizen-initiated ballot measures, including statutory initiatives and constitutional amendments (constitutional amendments by initiative must pass at two consecutive general elections). Cannabis itself was legalized via the 2016 citizen initiative Question 2. Source: https://www.mpp.org/states/nevada/ and https://www.leg.state.nv.us/

No pending statewide cannabis, psychedelic, or drug-policy citizen ballot measure for 2026 was identified in the sources reviewed; treat the existence of any 2026 measure as unconfirmed/none-found. Reform energy in this cycle has run through the legislature and the executive working group rather than the ballot. Source: https://thenevadaindependent.com/article/nevada-policy-tracker-a-quick-guide-to-key-issues-in-the-2025-legislative-session

Equity and expungement

Social equity: Nevada's cannabis statutes and CCB rules do not center a robust social-equity licensing program comparable to some other states; the 2025 reforms were oriented toward reducing operator fees and penalties rather than expanding equity ownership. Specific social-equity license set-asides are not documented in the sources reviewed and should be treated as unconfirmed. Source: https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/ and https://ccb.nv.gov/

Expungement/record sealing: Nevada uses petition-based record sealing, not automatic expungement. AB 192 (2019) lets people with now-decriminalized or legalized marijuana convictions petition to seal those records without a fee. Because relief is petition-based, it benefits those who know about and pursue the process and effectively excludes those who do not file; there is no automatic statewide sealing mechanism. Source: https://norml.org/news/2019/06/06/nevada-governor-signs-measure-sealing-past-marijuana-convictions/ and https://ccresourcecenter.org/state-restoration-profiles/nevada-restoration-of-rights-pardon-expungement-sealing/

Market and barriers

Taxes: 10% adult-use retail excise tax plus 15% wholesale excise tax on fair market value at transfer. Source: https://nevadastatecannabis.org/laws

License fees: SB 195 (2025) eliminated and capped multiple CCB fees and reassessed penalties, reportedly saving some operators tens of thousands of dollars per year; specific current fee schedules are set by the CCB. Source: https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/

License caps and counts: Nevada caps retail licenses (historically allocated by county/population) and requires dual state-plus-local approval, with significant MSO presence. Exact current license caps and the precise number of active licensees are set and published by the CCB and are not stated with a hard number in the sources reviewed; treat specific counts as unconfirmed pending CCB data. Source: https://ccb.nv.gov/ and https://nevadastatecannabis.org/laws

Capital/residency requirements: Specific capital minimums and any residency requirements are governed by CCB licensing rules and are not quantified in the sources reviewed; treat as unconfirmed. Source: https://ccb.nv.gov/laws-regulations/

Enclosure read

Who is being fenced out: small operators and new entrants face a capped, dual-approval, vertically capable, MSO-heavy market; home growers are largely excluded by the 25-mile rule (most urban residents cannot legally grow); and the 2025 hemp law (SB 356) pulled intoxicating hemp out of independent convenience-store and gas-station retail and into the licensed dispensary channel, eliminating a low-barrier path for small hemp sellers. The federal November 12, 2026 hemp redefinition further tightens this. Who is consolidating: incumbent licensed cannabis operators and MSOs, who gained fee relief and the merged dual license in 2025 and who now capture the formerly independent intoxicating-hemp market.

Justification for score 4/5: The market is licensed, capped, and dual-approval gated; home grow is effectively off-limits to most residents; intoxicating hemp has been routed to incumbent dispensaries; and there is no broad decriminalization, no social-equity license program documented, and only petition-based (non-automatic) record sealing. It is not a 5 because cannabis is fully legal with a functioning consumer market, consumption lounges are opening, harm-reduction distribution is active, and the citizen-initiative path remains available. Net: heavily fenced with some open edges, hence 4/5.

What to watch next

November 12, 2026: federal hemp redefinition (total-THC standard, ~0.4 mg/container product cap) takes effect; watch for CCB guidance reconciling SB 356 with the new federal definition. Source: https://legislativeanalysis.org/wp-content/uploads/2025/12/Hemp-Loophole-Fact-Sheet.pdf
February 2027: next regular biennial legislative session convenes; expect renewed psychedelic-therapy legislation (post-AB 378) and possible follow-on cannabis/hemp bills. Source: https://www.leg.state.nv.us/
Psychedelic Medicines Working Group recommendations remain the template for a future regulated-access bill. Source: https://www.dhs.nv.gov/Resources/Psychedelic_Medicines_Working_Group
Consumption lounge rollout in Las Vegas (additional CCB approvals). Source: https://www.reviewjournal.com/news/politics-and-government/nevada/3-more-marijuana-consumption-lounges-coming-to-nevada-2892180/
CCB rulemaking implementing the 2025 statutory changes (fees, labeling, hemp). Source: https://ccb.nv.gov/laws-regulations/

Regulators

Cannabis Compliance Board (CCB): licenses and enforces all medical and adult-use cannabis, including consumption lounges and (post-SB 356) intoxicating hemp sold through dispensaries. https://ccb.nv.gov/
Nevada Department of Health and Human Services (DHHS) / Division of Public and Behavioral Health: houses the Psychedelic Medicines Working Group and would have administered the proposed psychedelic pilot; oversees behavioral health and overdose programs. https://www.dhs.nv.gov/Resources/Psychedelic_Medicines_Working_Group
Nevada Department of Agriculture: historically regulates the hemp program/registration (verify scope after SB 356). https://agri.nv.gov/
Office of the Attorney General / Statewide Substance Use Response Working Group (SURG): coordinates opioid-settlement and overdose/treatment strategy. https://ag.nv.gov/
Local jurisdictions (e.g., Clark County, City of Las Vegas, Washoe County): co-approve cannabis establishments under the dual licensing framework.

Federal exposure (2026)

Rescheduling and 280E: Cannabis remains Schedule I by federal default. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; recreational cannabis stays Schedule I. The broader DEA rescheduling hearing opened June 29, 2026 and may slip to 2027. Because Nevada runs both an adult-use and a medical program, the split matters: the state's medical cannabis category gains relief from IRC Section 280E (the provision that bars normal business deductions for sellers of Schedule I/II substances), while the adult-use side, which is the dominant revenue channel tied to Las Vegas tourism, does not. Nevada's 2025 merger of medical and adult-use retail into a single "dual license" blurs that line operationally, but the federal tax treatment turns on the substance's schedule and the medical-versus-recreational character of the sale, not the state license type, so most Nevada dispensary revenue stays under 280E and stays Schedule I. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not cover state recreational businesses. Source: https://www.marijuanamoment.net/

The November 12, 2026 hemp cliff: The FY2026 agriculture appropriations rider (Section 781, sponsor Rep. Andy Harris R-MD) narrows hemp to a total-THC standard (roughly 0.4 mg THC per container), recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026. The H.R. 7010 delay was not enacted, and the 2026 Farm Bill (H.R. 7567) keeps the ban. Nevada is comparatively well positioned. Its 2025 SB 356 already routed intoxicating hemp (delta-8, delta-10, THC-O, HHC, high-THC items) out of convenience stores and gas stations and into licensed dispensaries only, so the federal ban largely aligns with where Nevada already pushed these products. Practical effect: the federal change reinforces SB 356 rather than upending it; intoxicating hemp that survives is already inside the regulated cannabis channel, and the federal floor squeezes any remaining unregulated sellers and removes the interstate hemp-THC supply that fed the gray market. The unsettled edge is non-intoxicating CBD: the new federal total-THC definition (including THCA and isomers) is stricter than SB 356's 0.3 percent consumable-hemp line, so some compliant Nevada CBD products could fall foul of the federal container cap; treat the precise reconciliation as unconfirmed pending CCB and Department of Agriculture guidance. Source: https://legislativeanalysis.org/wp-content/uploads/2025/12/Hemp-Loophole-Fact-Sheet.pdf and https://www.cannabisbusinesstimes.com/hemp/news/15823852/s-house-passes-2026-farm-bill-intoxicating-hemp-product-ban-remains

Banking: SAFER Banking has stalled in a Republican Congress. Nevada cannabis operators, including the MSOs that dominate the market, remain cut off from normal banking, card payments, and federal lending, which raises the cost of capital and reinforces incumbent advantage (those with existing banking relationships and scale absorb cash-handling and compliance costs that price out small entrants). Source: https://www.marijuanamoment.net/

Psychedelics: Psilocybin, MDMA, and ibogaine remain Schedule I federally. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review, but there is no federal approval yet. In Nevada the 2025 pilot bill (AB 378) died and the SB 242 (2023) Psychedelic Medicines Working Group recommended a state-regulated access framework, but with no 2026 session the earliest state vehicle is 2027. A purely state therapeutic-access program (the working group template) would run into the same federal Schedule I wall that has constrained other states; the cleaner near-term federal pathway for Nevadans is FDA approval of a specific psychedelic medicine, which would convert that single substance to a prescribable Schedule III-style product without requiring state legislation. Source: https://www.dhs.nv.gov/Resources/Psychedelic_Medicines_Working_Group and https://www.marijuanamoment.net/

Fentanyl: The HALT Fentanyl Act (July 17, 2025) permanently placed fentanyl-related substances in Schedule I, hardening the federal penalty backdrop against which Nevada's standard controlled-substances structure operates; Nevada has no broad decriminalization to cushion this.

Harm reduction: Nevada is directly exposed to the SAMHSA guidance of April 24, 2026 that bars federal funds for fentanyl test strips, clean syringes, and sterile water, while still supporting naloxone. Nevada's active distribution program (in the most recent year, 108,050 fentanyl test strips, 58,400 xylazine test strips, and clean-supply distribution alongside 56,880 naloxone units) leans on federal and opioid-settlement money; the federal cut threatens the test-strip and syringe components specifically, leaving naloxone as the protected line item. This compounds Nevada's existing ambiguity over whether fentanyl test strips are exempt from the state paraphernalia definition (reportedly reverted January 1, 2024, treated as unconfirmed above). Source: https://www.southernnevadahealthdistrict.org/programs/substance-use-and-overdose-prevention/harm-reduction/ and https://ag.nv.gov/uploadedFiles/agnvgov/Content/About/Administration/7.9.25%20SURG%20PPT.pdf

Patient access and rights

This section covers what Nevada law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Nevada has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Nevada is not among them. The absence is the finding: a Nevada patient has no enforceable right to use their medicine in a hospital today.

Broader protections: Nevada protects a patient in one of the six areas, employment. NRS Section 678C.850 requires an employer to attempt a reasonable accommodation for a patient's medical cannabis use, unless it would threaten harm, impose undue hardship, or keep the employee from fulfilling their job (subsections (2) and (3)). A review of Chapter 678C found no protection for housing, parenting, an organ transplant list, or school enrollment, and the medical-care provision (subsection (1)) only declines to require insurers to cover cannabis. Those gaps are the finding.

Out-of-state patients: Nevada offers full reciprocity; under NRS 678C.470 it recognizes a valid nonresident medical card.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Nevada has not enacted a Ryan's Law. The broader protections above are a creature of Nevada law, not federal law.

Sources: Nevada patient protections, NRS Chapter 678C, Section 678C.850.

Analysis: the enclosure read in depth

Who is fenced out in Nevada: small operators and new entrants confront a market that is capped, vertically capable, MSO-heavy, and gated by dual state-plus-local approval (both CCB and the relevant county or city must sign off), so a single jurisdiction can foreclose entry even where state law would allow it. Home growers are excluded by the 25-mile rule, which is a near-total home-grow ban for urban Nevada: the overwhelming majority of the population lives in metro Las Vegas (Clark County) and Reno (Washoe County) within 25 miles of an operating dispensary, so legal personal cultivation is realistically available only to rural residents. SB 356 (2025) removed the low-barrier intoxicating-hemp path that convenience stores, gas stations, and smoke shops had used, pulling that revenue into the licensed dispensary channel. The result is that the actors who could most cheaply enter (independent retailers, would-be craft growers, home cultivators) are systematically routed out.

Who consolidates: incumbent licensed cannabis operators and MSOs. The 2025 session handed them fee cuts and caps (SB 195), a merged dual retail/medical license that lets a single licensee serve both customer bases, and, via SB 356, the formerly independent intoxicating-hemp market. They are the parties positioned to absorb cash-only banking costs, dual-approval friction, and compliance overhead.

State-plus-federal interaction: the federal layer mostly reinforces the state enclosure rather than cutting against it. The November 12, 2026 hemp cliff federalizes the squeeze SB 356 already started, killing the interstate gray-market supply that small sellers relied on; stalled SAFER Banking keeps capital scarce in a way that favors scaled incumbents; continued Schedule I status for recreational cannabis keeps 280E on the dominant revenue line, which again rewards operators with the accounting sophistication and margin to manage it; and the medicalize-and-control federal posture (medical-only Schedule III relief, FDA-gated psychedelics) channels future openings toward large, capitalized, FDA-capable incumbents rather than community or small-scale actors. The one place state and federal diverge is non-intoxicating CBD, where the stricter federal total-THC container cap could catch products SB 356 allows, an unconfirmed friction point.

What to watch: CCB and Department of Agriculture guidance reconciling SB 356 with the federal total-THC definition before November 12, 2026; whether the DEA rescheduling hearing produces anything beyond the medical-only Schedule III move (and whether it slips to 2027); the fate of Nevada's harm-reduction test-strip and syringe funding under the April 2026 SAMHSA bar; and the February 2027 session as the next and only near-term vehicle for a psychedelic-access bill or any home-grow or social-equity expansion.

Where commons counter-moves are limited: Nevada's biennial legislature holds no regular 2026 session, so the legislative channel is closed until February 2027, removing the fastest counter-lever for two years. The citizen-initiative path remains formally open (cannabis itself came via Question 2 in 2016), but it is slow and, for a constitutional amendment, requires passage at two consecutive general elections. There is no documented social-equity licensing program to widen ownership, record relief is petition-based rather than automatic, and the executive working group on psychedelics can only recommend, not enact. So the practical commons responses, namely legislation, equity carve-outs, and home cultivation, are each either time-locked, absent, or narrowly drawn.

Justification for the enclosure score (4/5): the market is licensed, capped, dual-approval gated, and MSO-dominated; home grow is off-limits to nearly all urban residents; intoxicating hemp is routed to incumbent dispensaries and the federal cliff hardens that; banking scarcity and 280E favor scale; there is no broad decriminalization, no documented social-equity program, only petition-based sealing, and no 2026 legislative session to push back. It is not a 5 because cannabis is fully legal with a functioning consumer market, consumption lounges are opening, harm-reduction distribution is active (for now), and the citizen-initiative path remains available. Heavily fenced with a few open edges, hence 4/5.

Active legislation (2026)

Nevada's legislature is biennial and meets in regular session only in odd-numbered years. There is no regular legislative session in 2026 and therefore no active 2026 drug-policy bills; the items below are the significant 2025 (83rd Session) outcomes that define current law going into 2026. The next regular session convenes in February 2027.

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

SB 195 (2025) Cannabis fee cuts/caps, penalty reassessment, merged dual retail/medical license (Enacted (signed 2025))
SB 242 (2023) Psychedelic Medicines Working Group (study and recommendations) (Enacted (2023); report delivered)

Bill	Title/Topic	Chamber	Status	Sponsor(s)
SB 356 (2025)	Intoxicating hemp routed to licensed dispensaries only; consumable hemp definition	Senate	Enacted (signed 2025)	unconfirmed (Senate Commerce and Labor measure; verify on LegiScan)
AB 504 (2025)	Deceptive-trade-practice provisions for unlicensed hemp sellers	Assembly	Enacted	unconfirmed
SB 195 (2025)	Cannabis fee cuts/caps, penalty reassessment, merged dual retail/medical license	Senate	Enacted (signed 2025)	unconfirmed
SB 168 (2025)	Cannabis packaging/labeling, usable cannabis definition, single-package THC limits	Senate	Enacted	unconfirmed
SB 41 (2025)	Requires cannabis tax permit tied to license	Senate	Enacted	unconfirmed
SB 25 (2025)	State Fire Marshal inspection authority over cannabis production facilities	Senate	Enacted	unconfirmed
AB 378 (2025)	Alternative Therapy (psychedelics) Pilot Program for veterans/first responders	Assembly	Died (passed committee, no final passage)	Sponsors per reporting Sen. Nguyen and Asm. Carter; verify on official record
SB 242 (2023)	Psychedelic Medicines Working Group (study and recommendations)	Senate	Enacted (2023); report delivered	unconfirmed

This list is not exhaustive. For the full long tail and any 2027 prefiled measures, use the live trackers: LegiScan Nevada (https://legiscan.com/NV), the Nevada Legislature site (https://www.leg.state.nv.us/), and Marijuana Moment's bill tracker (https://www.marijuanamoment.net/). Source: https://connorpllc.com/2025-legislative-session-relating-to-cannabis/ and https://legiscan.com/NV/bill/SB168/2025 and https://mjbizdaily.com/nevada-marijuana-companies-cite-big-wins-from-legislative-session/

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →